Boston Scientific offers $4.3 billion fixed-rate notes in five parts

By Devika Patel

Knoxville, Tenn., Feb. 21 – Boston Scientific Corp. plans to price a five-part offering of fixed-rate senior notes, according to a 424B5 filing with the Securities and Exchange Commission. S&P Global Ratings reported that the deal would be for $4.3 billion.

All of the notes (BBB-/BBB) will have a make-whole call and then a par call.

Barclays, BofA Merrill Lynch and Wells Fargo Securities LLC are the bookrunners.

Proceeds will be used to fund some of the company's planned acquisition of BTG plc, to redeem its $850 million of 6% notes due January 2020 and $600 million of 2.85% notes due May 2020, to repay debt under its $1 billion term loan facility due August 2019 and to repay other short-term debt.

Boston Scientific is a medical device maker based in Marlborough, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.